Stanford tests Brain-Targeting drug for depression relief
NCT ID NCT06408246
Summary
This study aims to understand if adding the medication guanfacine to a standard antidepressant (sertraline) can improve brain network function and help reduce depression symptoms, particularly for people who also experience thinking and concentration problems. Researchers will enroll 162 adults aged 18-60 with depression and track their symptoms, brain activity via MRI scans, and daily functioning over an 8-week treatment period. Participants will be randomly assigned to receive either guanfacine or a placebo, in addition to sertraline, to compare the effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford Psychiatry and Behavioral Sciences Department
RECRUITINGPalo Alto, California, 94305, United States
-
University of Illinois at Chicago
RECRUITINGChicago, Illinois, 60607, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.